



Clinical trial results:

MESI-STRAT WOO 2 Trial / MESI-STRAT

**Prospective Window of opportunity trial of 3 weeks neoadjuvant
Anastrozole in Postmenopausal Women with Estrogen receptor positive
(ER+) Breast Cancer: WOO 2**

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2020-003960-22 |
| Trial protocol | AT |
| Global end of trial date | 09 June 2023 |

Results information

| | |
|-----------------------------------|----------------------------------------------------------------------------------------------------------------|
| Result version number | v1 (current) |
| This version publication date | 22 June 2024 |
| First version publication date | 22 June 2024 |
| Summary attachment (see zip file) | Justification letter non-reported endpoints (MESI STRAT WOO2 Justification Letter Non-Reported End Points.pdf) |

Trial information

Trial identification

| | |
|-----------------------|------|
| Sponsor protocol code | WOO2 |
|-----------------------|------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Sponsor organisation name | Medizinische Universität Innsbruck |
| Sponsor organisation address | Innrain 52, Innsbruck, Austria, 6020 |
| Public contact | Regina Berger, Medizinische Universität Innsbruck Univ.-Klinik f. Gynäkologie und Geburtshilfe, regina.berger@i-med.ac.at |
| Scientific contact | Daniel Egle, Medizinische Universität Innsbruck Univ.-Klinik f. Gynäkologie und Geburtshilfe, Daniel.Egle@tirol-kliniken.at |

Notes:

Paediatric regulatory details

| | |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|------------------------------------------------------|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 29 November 2023 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 09 June 2023 |
| Global end of trial reached? | Yes |
| Global end of trial date | 09 June 2023 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

Comparison of kynurenine concentration before and after 21 days treatment with Anastrozole

Protection of trial subjects:

The trial medication Anastrozole is a standard of care therapy for postmenopausal women. For ethical reasons only women that would receive an aromatase inhibitor after surgery will be included in the WOO 2 trial. Therefore only the sequence of aromatase inhibitor application will be altered as Anastrozole will be given for 3 weeks before routine surgery as opposed to its regular adjuvant application. Anastrozole is well known and approved by Austrian regulatory authorities for the treatment of postmenopausal ER+ BC patients. Due to its safety profile we expect only few serious adverse events (SAEs) to occur. All relevant safety information can be found in the Summary of Product Characteristics (SmPC). The IMU is experienced in neoadjuvant administration of Anastrozole.

Background therapy: -

Evidence for comparator: -

| | |
|-----------------------------------------------------------|------------------|
| Actual start date of recruitment | 02 November 2020 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------|
| Country: Number of subjects enrolled | Austria: 56 |
| Worldwide total number of subjects | 56 |
| EEA total number of subjects | 56 |

Notes:

Subjects enrolled per age group

| | |
|-------------------------------------------|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |

| | |
|---------------------------|----|
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 18 |
| From 65 to 84 years | 38 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

A total of 50 patients, who have received treatment, are required for analysis. Screening failure but not the drop-out rate is expected to be high, recruitment will commence once a total of 50 patients have started treatment.

Pre-assignment

Screening details:

During the screening phase the eligibility of the patient is assessed. The screening visit includes verification of all inclusion and exclusion criteria. Written informed consent is obtained. No trial specific interventions were made prior to written consent of the patient.

Pre-assignment period milestones

| | |
|------------------------------|----|
| Number of subjects started | 56 |
| Number of subjects completed | 56 |

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Pre-treatment (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Arms

| | |
|----------------------------------------|------------------|
| Arm title | All participants |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | ARIMIDEX 1mg |
| Investigational medicinal product code | |
| Other name | Anastrozole |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

1 mg per day orally

| Number of subjects in period 1 | All participants |
|-------------------------------------------------|------------------|
| Started | 56 |
| Completed | 52 |
| Not completed | 4 |
| Consent withdrawn by subject | 3 |
| No surgery possible due to atrial fibrillation. | 1 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|------------------|
| Reporting group title | All participants |
|-----------------------|------------------|

Reporting group description: -

| Reporting group values | All participants | Total | |
|------------------------|------------------|-------|--|
| Number of subjects | 56 | 56 | |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 18 | 18 | |
| From 65-84 years | 38 | 38 | |
| 85 years and over | 0 | 0 | |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 69.1 | | |
| standard deviation | ± 8.4 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 56 | 56 | |

End points

End points reporting groups

| | |
|--------------------------------|------------------|
| Reporting group title | All participants |
| Reporting group description: - | |

Primary: kynurenine level (KYN)

| | |
|------------------------|---------------------------------------|
| End point title | kynurenine level (KYN) ^[1] |
| End point description: | |

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Before treatment start and directly after 21 days of neoadjuvant Anastrozole therapy.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Single arm study.

| | | | | |
|--------------------------------------|--------------------|--|--|--|
| End point values | All participants | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 51 | | | |
| Units: μM | | | | |
| arithmetic mean (standard deviation) | 1.57 (\pm 0.48) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: change in Ki67 expression

| | |
|------------------------|---------------------------|
| End point title | change in Ki67 expression |
| End point description: | |

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

21 days

| | | | | |
|--------------------------------------|--------------------|--|--|--|
| End point values | All participants | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 51 | | | |
| Units: percent | | | | |
| arithmetic mean (standard deviation) | 8.65 (\pm 5.30) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: MESI network

| | |
|-----------------|--------------|
| End point title | MESI network |
|-----------------|--------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

21 days

| | | | | |
|----------------------------------|--------------------|--|--|--|
| End point values | All participants | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 51 | | | |
| Units: micromole(s) | | | | |
| median (confidence interval 95%) | 6.1 (3.94 to 8.46) | | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Investigators collected adverse events (AEs) during measurements on all study days. The observation period started with the first IMP administration (preceded by medical history) and ended at the last study visit, about four weeks after the final dose.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 27.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|------------------|
| Reporting group title | All participants |
|-----------------------|------------------|

Reporting group description: -

| Serious adverse events | All participants | | |
|---------------------------------------------------|------------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 56 (1.79%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | | | |
| Cardiac disorders | | | |
| Infection-triggered cardiac decompensation | | | |
| subjects affected / exposed | 1 / 56 (1.79%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | All participants | | |
|-------------------------------------------------------|------------------|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 22 / 56 (39.29%) | | |
| Vascular disorders | | | |
| Hot flashes | | | |
| subjects affected / exposed | 8 / 56 (14.29%) | | |
| occurrences (all) | 8 | | |
| Nervous system disorders | | | |
| Headache | | | |

| | | | |
|------------------------------------------------------------------------------------------------------------------------|----------------------|--|--|
| subjects affected / exposed occurrences (all) | 6 / 56 (10.71%) 6 | | |
| General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all) | 5 / 56 (8.93%) 5 | | |
| Gastrointestinal disorders Nausea subjects affected / exposed occurrences (all) | 5 / 56 (8.93%) 6 | | |
| Psychiatric disorders Insomnia subjects affected / exposed occurrences (all) | 4 / 56 (7.14%) 5 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|---------------------|
| 01 February 2023 | Change in timeline. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported